AEON Biopharma Files S-1/A Amendment

TL;DR

AEON Biopharma (fka Priveterra) filed S-1/A on 7/23. Pharma prep company.

AI Summary

AEON Biopharma, Inc. filed an S-1/A amendment on July 23, 2024, for its registration statement. The company, previously known as Priveterra Acquisition Corp. until December 22, 2020, is incorporated in Delaware and operates in the Pharmaceutical Preparations sector. Its principal executive offices are located at 5 Park Plaza, Suite 1750, Irvine, California.

Why It Matters

This filing indicates AEON Biopharma is continuing its process of registering securities, which is a step towards potential public offerings or other capital-raising activities.

Risk Assessment

Risk Level: medium — S-1/A filings are typically associated with companies seeking to raise capital, which can involve inherent risks for investors depending on the company's stage and market conditions.

Key Numbers

• 333-274094 — SEC File Number (Identifies the specific registration statement)
• 0001837607 — Central Index Key (Unique identifier for the filer)

Key Players & Entities

• AEON Biopharma, Inc. (company) — Registrant
• Priveterra Acquisition Corp. (company) — Former company name
• July 23, 2024 (date) — Filing date
• December 22, 2020 (date) — Date of name change
• Alex Wilson (person) — Chief Legal Officer
• 5 Park Plaza, Suite 1750 Irvine, California 92614 (address) — Principal executive offices

FAQ

Key Financial Figures

• $0.0001 — ares of Class A common stock, par value $0.0001 per share (the "Common Stock") issued i
• $10.00 — s") at an equity consideration value of $10.00 per share, (ii) the resale of 400,000 s
• $1.00 — where in this prospectus) at a price of $1.00 per share (assuming the maximum accrued
• $7.00 — where in this prospectus) at a price of $7.00 per share, (v) the issuance and resale
• $1.50 — vate Placement Warrants") at a price of $1.50 per warrant, by the holders thereof.
• $0.10 — lic Warrants, for a redemption price of $0.10 per Public Warrant, that remained outst
• $45.9 million — ive up to an aggregate of approximately $45.9 million from the cash exercise of the Private P
• $11.50 — ch of our Private Placement Warrants is $11.50 per warrant and the last reported sales
• $2.35 — f our Common Stock on July 22, 2024 was $2.35. The likelihood that holders of Private
• $0.004 — rospectus) purchased by the Sponsor for $0.004 per share prior to Priveterra's initial
• $3.0 billion — th the goal of addressing the estimated $3.0 billion global therapeutic botulinum toxin mark
• $4.4 billion — n market, which is projected to grow to $4.4 billion in 2027, according to the Decision Reso

Filing Documents

• tm2415597-4_s1a.htm (S-1/A) — 5253KB
• tm2415597d5_ex5-1.htm (EX-5.1) — 23KB
• tm2415597d5_ex23-1.htm (EX-23.1) — 2KB
• tm2415597d5_ex23-2.htm (EX-23.2) — 2KB
• tm2415597d5_ex-filingfees.htm (EX-FILING FEES) — 91KB
• lg_aeonbiopharma-4c.jpg (GRAPHIC) — 14KB
• tm2415597d5_ex5-1img001.jpg (GRAPHIC) — 4KB
• tm2415597d5_ex5-1img002.jpg (GRAPHIC) — 2KB
• 0001104659-24-081925.txt ( ) — 5401KB

USE OF PROCEEDS

USE OF PROCEEDS 63 DIVIDEND POLICY 64

MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS 65

BUSINESS

BUSINESS 89 MANAGEMENT 112 EXECUTIVE AND DIRECTOR COMPENSATION 118 CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS 135 PRINCIPAL STOCKHOLDERS 145 REGISTERED HOLDERS 147 DESCRIPTION OF OUR SECURITIES 158 PLAN OF DISTRIBUTION 170 LEGAL MATTERS 173 EXPERTS 174 WHERE YOU CAN FIND MORE INFORMATION 175 INDEX TO FINANCIAL STATEMENTS F-1 i TABLE OF CONTENTS ABOUT THIS PROSPECTUS This prospectus is part of a registration statement that we filed with the United States Securities and Exchange Commission, or the SEC, using a "shelf" registration process. We will not receive any proceeds from the sale by the Registered Holders of the securities offered by them described in this prospectus. This prospectus also relates to the issuance by us of the shares of Common Stock issuable upon the exercise of the Warrants. We will not receive any proceeds from the sale of shares of Common Stock underlying the Warrants pursuant to this prospectus, except with respect to amounts received by us upon the exercise of the Warrants for cash. We may also file a prospectus supplement or post-effective amendment to the registration statement of which this prospectus forms a part that may contain material information relating to these offerings. The prospectus supplement or post-effective amendment may also add, update or change information contained in this prospectus with respect to that offering. If there is any inconsistency between the information in this prospectus and the applicable prospectus supplement or post-effective amendment, you should rely on the prospectus supplement or post-effective amendment, as applicable. Before purchasing any securities, you should carefully read this prospectus, any post-effective amendment, and any applicable prospectus supplement, together with the additional information described under the heading " Where You Can Find More Information ." Neither we nor the Registered Holders have authorized anyo

View Full Filing

View this S-1/A filing on SEC EDGAR